Co-Diagnostics received an Australian trademark, with the official introduction to its robust platform and property

Announcement

Co-Diagnostics, Inc., a leading molecular diagnostics company with a remarkable patented platform for the establishment of molecular diagnostics tests, today proudly announced that it has received a patent right from the Australian Patent Office. The Australian Patent No. AU2022270084A1 fortifies the company’s intellectual property portfolio encompassing its novel Co-Dx PCR platform. This patent is an encouragement, a confidence to build an ethical business and introduce its operations with certain required confirmation to gain trust.

This trademark is paving the way for the company’s next-generation advancement and development in Australia. Most of the individuals in this region are suffering from the flu, and the healthcare sector is in urgent need to deliver the best treatment for their condition. This patent right is a relief for these individuals, who will largely contribute to the region's healthcare sector soon. Co-Diagnostics has always been a promising company when it comes to its comprehensive platform technologies that only serve accuracy and efficiency.

CEO of Co-Dx, Dwight Egan, said, “This patent right marks a valuable milestone in preserving a shield for our technology as we are proceeding towards extending the qualified and significant applications of the point-of-care PCR platform. From the start, the company’s main goal is to introduce accessible and perfect PCR testing available in the areas where it's needed the most and bolster our universal IP portfolio. This portfolio is fundamental to that mission.”

Patent Right to bring new change in Co-Dx footprint

The patent right in Australia is like a strategic protection in a particular region where Co-Dx and other capable marketing partners can have the authority to distribute and showcase the Co-Dx PCR platform in the future. The region has currently witnessed an extreme flu season, and this patent right in the market delivers as a major defensive measure to secure the marketing potential of the platform. It also involves Co-Dx RSV multiplex test (ongoing in clinical performance testing space), COVID, and PCR Flu A/B.

About the Co-Dx PCR platform

The Co-Diagnostics’ Co-Dx PCR platform is engineered to serve a standardised and excellent PCR accuracy in the smallest and easiest form, user friendly device, perfect for the decentralised testing environments. The platform accelerates the Company’s trademarked Co-Primers® technology and has planned to allow sensitive, particular and rapid molecular diagnostics throughout a wide number of infectious disease applications.